Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations
Abstract Introduction The predictive utility of laboratory markers in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations treated with tyrosine kinase inhibitors (TKIs) is an ongoing area of research. The predictability of the platelet-lymphocyte ratio (PLR) on survival outcome...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-11-01
|
| Series: | Discover Oncology |
| Online Access: | https://doi.org/10.1007/s12672-024-01606-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850129262927937536 |
|---|---|
| author | Ryan Cooper Dhruv Ramaswami Jacob S. Thomas Jorge J. Nieva Robert Hsu |
| author_facet | Ryan Cooper Dhruv Ramaswami Jacob S. Thomas Jorge J. Nieva Robert Hsu |
| author_sort | Ryan Cooper |
| collection | DOAJ |
| description | Abstract Introduction The predictive utility of laboratory markers in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations treated with tyrosine kinase inhibitors (TKIs) is an ongoing area of research. The predictability of the platelet-lymphocyte ratio (PLR) on survival outcomes depending on the generation of EGFR TKI is undetermined. Methods 151 patients treated with EGFR TKIs in Los Angeles were grouped according to generation of TKI. Differences in progression free survival (PFS) by stratification by PLR was determined using Kaplan–Meier analysis. Differences in median change in laboratory markers by generation of TKI was analyzed using Mann–Whitney tests. Cox Hazard Regression was used to perform multivariate analysis. Results Median PFS of those managed with 1st or 2nd generation TKIs was significantly lower in patients with a PLR ≥ 180 (10.5 months) compared to those with PLR < 180 (16.6 months, p = 0.0163). Median PFS was comparable in those treated with osimertinib regardless of PLR. Patients managed with osimertinib had a significant decrease in absolute lymphocyte count (ALC) at 6 weeks and in platelets at 6 weeks and 3 months compared to those managed with 1st or 2nd generation TKIs. Discussion The predictive value of PLR was more apparent in patients treated with 1st or 2nd generation TKIs compared to those treated with osimertinib. Third generation EGFR TKIs may be more efficacious in treating patients with laboratory findings previously shown to predict poor survival. The significant changes in peripheral cell counts suggest variable tumor microenvironment changes dependent on the generation of TKI received. |
| format | Article |
| id | doaj-art-a3d458b691654965bc60fe0d3dad6763 |
| institution | OA Journals |
| issn | 2730-6011 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-a3d458b691654965bc60fe0d3dad67632025-08-20T02:33:02ZengSpringerDiscover Oncology2730-60112024-11-0115111010.1007/s12672-024-01606-9Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generationsRyan Cooper0Dhruv Ramaswami1Jacob S. Thomas2Jorge J. Nieva3Robert Hsu4University of Southern California Keck School of MedicineUniversity of Southern CaliforniaDepartment of Internal Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern CaliforniaDepartment of Internal Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern CaliforniaDepartment of Internal Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern CaliforniaAbstract Introduction The predictive utility of laboratory markers in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations treated with tyrosine kinase inhibitors (TKIs) is an ongoing area of research. The predictability of the platelet-lymphocyte ratio (PLR) on survival outcomes depending on the generation of EGFR TKI is undetermined. Methods 151 patients treated with EGFR TKIs in Los Angeles were grouped according to generation of TKI. Differences in progression free survival (PFS) by stratification by PLR was determined using Kaplan–Meier analysis. Differences in median change in laboratory markers by generation of TKI was analyzed using Mann–Whitney tests. Cox Hazard Regression was used to perform multivariate analysis. Results Median PFS of those managed with 1st or 2nd generation TKIs was significantly lower in patients with a PLR ≥ 180 (10.5 months) compared to those with PLR < 180 (16.6 months, p = 0.0163). Median PFS was comparable in those treated with osimertinib regardless of PLR. Patients managed with osimertinib had a significant decrease in absolute lymphocyte count (ALC) at 6 weeks and in platelets at 6 weeks and 3 months compared to those managed with 1st or 2nd generation TKIs. Discussion The predictive value of PLR was more apparent in patients treated with 1st or 2nd generation TKIs compared to those treated with osimertinib. Third generation EGFR TKIs may be more efficacious in treating patients with laboratory findings previously shown to predict poor survival. The significant changes in peripheral cell counts suggest variable tumor microenvironment changes dependent on the generation of TKI received.https://doi.org/10.1007/s12672-024-01606-9 |
| spellingShingle | Ryan Cooper Dhruv Ramaswami Jacob S. Thomas Jorge J. Nieva Robert Hsu Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations Discover Oncology |
| title | Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations |
| title_full | Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations |
| title_fullStr | Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations |
| title_full_unstemmed | Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations |
| title_short | Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations |
| title_sort | assessing the predictive role of platelet lymphocyte ratio in egfr mutated non small cell lung cancer patients treated with tyrosine kinase inhibitors an analysis across tki generations |
| url | https://doi.org/10.1007/s12672-024-01606-9 |
| work_keys_str_mv | AT ryancooper assessingthepredictiveroleofplateletlymphocyteratioinegfrmutatednonsmallcelllungcancerpatientstreatedwithtyrosinekinaseinhibitorsananalysisacrosstkigenerations AT dhruvramaswami assessingthepredictiveroleofplateletlymphocyteratioinegfrmutatednonsmallcelllungcancerpatientstreatedwithtyrosinekinaseinhibitorsananalysisacrosstkigenerations AT jacobsthomas assessingthepredictiveroleofplateletlymphocyteratioinegfrmutatednonsmallcelllungcancerpatientstreatedwithtyrosinekinaseinhibitorsananalysisacrosstkigenerations AT jorgejnieva assessingthepredictiveroleofplateletlymphocyteratioinegfrmutatednonsmallcelllungcancerpatientstreatedwithtyrosinekinaseinhibitorsananalysisacrosstkigenerations AT roberthsu assessingthepredictiveroleofplateletlymphocyteratioinegfrmutatednonsmallcelllungcancerpatientstreatedwithtyrosinekinaseinhibitorsananalysisacrosstkigenerations |